Benefit–Risk Summary of Nivolumab for the Treatment of Patients with Unresectable Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma After Prior Fluoropyrimidine- and Platinum-Based Chemotherapy

Lorraine Pelosof, May Tun Saung, Martha Donoghue, Sandra Casak, Sirisha Mushti, Joyce Cheng, Xiling Jiang, Jiang Liu, Hong Zhao, Maryam Khazraee, Kirsten B. Goldberg, Marc Theoret, Steven Lemery, Richard Pazdur, Lola Fashoyin-Aje

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Benefit–Risk Summary of Nivolumab for the Treatment of Patients with Unresectable Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma After Prior Fluoropyrimidine- and Platinum-Based Chemotherapy'. Together they form a unique fingerprint.

Medicine & Life Sciences